The SEER database, which covers roughly half of the U.S. population across 22 geographic regions, is a cornerstone for population-based cancer research, capturing critical demographic, clinical, and survival information. Yet, this new analysis conducted by researchers at the University of Minnesota and Moffitt Cancer Center demonstrates a worrisome trend: patients with incomplete records have significantly poorer outcomes and are more commonly treated outside of Commission on Cancer (CoC)-accredited centers. This skews the dataset toward a rosier picture of cancer survival than what truly exists across the nation’s heterogeneous healthcare landscape.

Evaluating over 328,000 cases diagnosed from 2018 to 2020 across four cancer types—breast, pancreas, colon, and non-small cell lung cancer (NSCLC)—the researchers systematically dissected how missing data correlates with treatment site accreditation and patient outcomes. They found that individuals receiving care at non-CoC accredited institutions were two to three times more likely to have incomplete data within SEER. For example, nearly 42% of NSCLC patients treated at these centers had missing records compared to just 13% at CoC-accredited facilities. This disparity is profoundly consequential for understanding nationwide cancer care effectiveness, particularly for marginalized groups.

The significance transcends mere statistical inconvenience. Patients omitted due to partial data demonstrated far lower three-year overall survival rates—between 18% to 36% worse—compared to their fully documented counterparts. This manifests not only a sampling bias but a systematic exclusion of older adults, rural populations, and socioeconomically disadvantaged individuals, many of whom present with more advanced-stage disease and face barriers to accessing comprehensive cancer therapies. These findings reveal a form of institutional erasure, whereby the most vulnerable cancer patients are invisibilized within major epidemiologic studies.

Dr. Schelomo Marmor, senior author and surgical oncology expert, highlights this phenomenon as a “blind spot” within oncologic data science. The notion that missingness in databases is benign or random is dispelled; instead, missing cases correlate with real-world social determinants and disease severity. Consequently, population-based research and survival analyses that exclude incomplete records risk painting overly optimistic pictures of cancer prognosis nationwide, which could misinform clinical guidelines and public health initiatives aimed at cancer control.

Furthermore, the study underscores emerging challenges as artificial intelligence (AI) and machine learning techniques increasingly leverage these registries. AI algorithms inherently learn patterns present in their training datasets, including deficiencies and biases. If patients with incomplete data—who are disproportionately high-risk—are excluded from training datasets, AI models will replicate and amplify these blind spots. This perpetuates inequities in predictive analytics, personalized treatment algorithms, and clinical decision support systems, ultimately compromising fair and accurate cancer care recommendations.

To address these limitations, the researchers advocate for integrating multiple data sources. For example, combining SEER data with the National Cancer Database (NCDB), a hospital-based registry emphasizing CoC-accredited centers, could counterbalance missingness and improve completeness. However, given that each source has intrinsic biases, harmonizing datasets and developing methodological approaches to robustly handle missing information will be essential to enhancing data fidelity and representativeness.

The root causes of missing data remain an open query demanding further inquiry. Potential factors include inadequate clinical documentation, understaffed cancer registries, variability in coding standards, and complexities associated with advanced disease management. Unpacking these causes is a critical next step to designing interventions that ensure all patients, especially the most vulnerable, are captured in cancer surveillance datasets.

This investigation, based on a large cohort and employing clinically validated statistical methods adjusting for age and hazard proportionality, marks a crucial advancement in understanding data completeness in oncology registries. It eloquently challenges the community to rethink reliance on single-source datasets and calls for transparency about missing data’s implications on clinical research and health equity.

In conclusion, this research lays bare an urgent need for oncologists, data scientists, and policymakers to confront the systemic exclusion of high-risk cancer patients in national databases. Without addressing these blind spots, studies may continue to present an overly rosy depiction of cancer survival, undermining efforts to recognize and rectify disparities. The era of AI-powered oncology research amplifies the stakes, demanding concerted efforts to develop inclusive, accurate, and equitable data infrastructures that truthfully reflect cancer’s impact across all populations.

Subject of Research: Cancer registry data completeness and its impact on survival estimates in SEER studies.

Article Title: Missing, but not Forgotten: Commission on Cancer Center Accreditation and the Impact of Missing Data in SEER Studies

News Publication Date: 14-May-2026

Web References:

• Journal of the American College of Surgeons Article
• American College of Surgeons
• National Cancer Database

References:
White MJ, Prathibha S, Luo Q, et al. Missing, but not Forgotten: Commission on Cancer Center Accreditation and the Impact of Missing Data in SEER Studies. Journal of the American College of Surgeons, 2026. DOI: 10.1097/XCS.0000000000001866

Keywords: cancer research, oncology, surgery, SEER database, missing data, health disparities, cancer survival, cancer registries, data completeness, Commission on Cancer accreditation, artificial intelligence, machine learning.

The study, conducted across the Texas Oncology Network and integrating diverse datasets including the County Health Rankings and Roadmaps Data, detailed patient journey milestones through four critical care junctures: diagnosis and evaluation, treatment plan design, treatment implementation, and end-of-life care. By focusing on the Medicare population with metastatic breast cancer, researchers aimed to dissect not just clinical outcomes, but also underlying non-clinical predictors that influence care quality and timeliness.

Importantly, the research cohort comprised 460 patients with an average age of 72.7 years, predominantly female, with a racial/ethnic distribution mainly of White (73.7%), Hispanic (10.7%), and Black (7.6%) individuals. Such demographic granularity allowed for a nuanced exploration of disparities, leveraging robust statistical approaches including bivariate analyses, multivariable logistic regressions, and generalized linear models to parse out the effects of race/ethnicity alongside a constructed "Vulnerability Cluster" of sociodemographic variables.

Findings revealed an ostensibly equitable landscape in the early and middle phases of metastatic breast cancer care — over 90% of patients received services during diagnosis, treatment planning, and treatment implementation. However, once patients transitioned to end-of-life care, a different narrative unfolded. Referral rates to palliative care were alarmingly low at just 3.04%, and only around one-third of patients were enrolled in hospice programs, metrics that signal systemic gaps in supportive care.

The most striking disparity emerged when examining hospice enrollment timing and length of stay (LOS) metrics. Black and Hispanic patients not only enrolled in hospice care significantly sooner after diagnosis relative to their White counterparts—showing 13.2% and 34.8% shorter timeframes, respectively—but also experienced notably abbreviated hospice stays, with decreases in LOS by approximately 24.6% and 25.3%. These truncated engagements with end-of-life care services raise critical concerns about the quality and comprehensiveness of care delivered.

Such results highlight a paradox where shorter hospice enrollment times, often presumed beneficial for early access, may in fact signal rushed or delayed referrals with consequential impacts on the quality of palliative support. The study underscores that these disparities persist even within a Medicare population expected to have uniform insurance coverage, thus spotlighting non-financial systemic barriers including cultural, geographic, and institutional factors.

Delving deeper into the Vulnerability Cluster, including sociodemographic and clinical characteristics, the researchers found that multiple factors beyond race/ethnicity significantly predicted disparities in care delivery. These elements collectively shape patient experiences and outcomes, suggesting that equitable care mandates multifaceted strategies addressing social determinants alongside medical interventions.

The implications extend beyond academic interest; they compel healthcare systems to re-examine operational protocols, provider education, and resource allocation aimed at mitigating inequities. The findings advocate for tailored interventions to ensure that patients with metastatic breast cancer, irrespective of racial or ethnic background, receive timely and comprehensive end-of-life care, including appropriate hospice and palliative referrals.

This study also prompts a reevaluation of current Medicare policies and oncology care models, encouraging integration of equity-centered metrics and incentivizing care pathways that diminish disparities. The revelation that even well-insured populations face such inequities highlights the intrinsic complexity of health disparities rooted in structural determinants.

Notably, the research provides a sober reminder of the inherent challenges in oncology care transitions — moments that are as clinically critical as they are emotionally charged for patients and families. Equitable access to quality care must extend through every phase of the metastatic cancer journey, embracing holistic approaches responsive to diverse patient needs.

Moreover, by emphasizing end-of-life disparities, the study challenges the oncology community to prioritize palliative care integration early and equitably, dismantling barriers linked to cultural mistrust, provider biases, and limited patient education. These systemic changes hold promise not only for enhancing care quality but also for improving patient dignity and quality of life in advanced disease stages.

Beyond the clinical sphere, the research shines a spotlight on the urgent need for public health initiatives and community engagement strategies that elevate awareness and trust in hospice services among minority populations. Such initiatives could bridge gaps observed in hospice utilization and referral timing, promoting culturally competent models of care.

Ultimately, the research underscores that while medical innovation continues to extend survival in metastatic breast cancer, equitable delivery of supportive care remains an unfinished frontier. The call for proactive, patient-centered, and culturally tailored care interventions resonates as a clarion demand from vulnerable populations whose experiences too often reflect systemic neglect.

As the medical and scientific community digests these findings, this study serves as both a benchmark and a blueprint—illuminating disparities with rigorous methodology, while charting a course toward more just and compassionate care for metastatic breast cancer patients approaching the end of life. The intersection of race, vulnerability, and care quality beckons ongoing research, policy reform, and clinical innovation.

The journey of metastatic breast cancer care is one marked by scientific advances and harrowing challenges. Ensuring that progress benefits all patients equitably demands not only technical innovation but profound commitment to social justice—a principle eloquently substantiated by this meticulous multi-site retrospective analysis.

Subject of Research: Determinants of disparities in care equity across treatment junctures in metastatic breast cancer patients under Medicare, with a focus on end-of-life care among diverse racial/ethnic groups.

Article Title: Assessing equity of care across metastatic breast cancer treatment junctures: a multi-site retrospective cohort study

Article References:
Brown, C., Kang, H.A., Johnsrud, M. et al. Assessing equity of care across metastatic breast cancer treatment junctures: a multi-site retrospective cohort study. BMC Cancer 25, 861 (2025). https://doi.org/10.1186/s12885-025-14172-2

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14172-2

Over recent decades, ERBB2-targeted therapies, including monoclonal antibodies and small molecule inhibitors, have revolutionized clinical outcomes for patients with this breast cancer subtype. However, persistent disparities in healthcare delivery have historically limited equitable access to these life-saving treatments among racial and ethnic minority populations, particularly among older Medicare beneficiaries. The newly presented data, emerging from a comprehensive analysis of Medicare records, suggest a significant narrowing of these discrepancies, signaling progress toward more equitable cancer care delivery.

This study meticulously analyzed treatment patterns over a defined period, accounting for various sociodemographic and clinical variables that influence therapeutic adoption. Advanced statistical methodologies were employed to discern trends in the receipt of ERBB2-targeted agents, revealing that minority patients are increasingly benefiting from these innovations at rates closer to their non-minority counterparts. Such findings herald an important milestone in addressing structural inequities that have long beleaguered oncology care in the United States.

The significance of these results extends beyond mere numbers; they underscore a subtle but meaningful shift in healthcare practices, policy frameworks, and possibly provider behaviors that collectively foster improved access to cutting-edge interventions. Importantly, the research does not merely quantify disparities but invites a deeper inquiry into the mechanisms driving this narrowing gap. Understanding these factors could catalyze the design of implementation strategies that embed equity at their core, ultimately elevating the standard of breast cancer care nationwide.

ERBB2-positive breast cancer, characterized by the overexpression of the receptor tyrosine-protein kinase erbB-2, manifests with aggressive clinical features, including rapid tumor growth and metastasis. Targeted therapies against this receptor have demonstrated remarkable efficacy by inhibiting downstream signaling pathways critical for tumor cell survival and proliferation. As such, timely and appropriate administration of these therapies is pivotal for improving survival outcomes.

From a clinical perspective, the study’s findings may reflect enhanced dissemination of clinical practice guidelines emphasizing the importance of ERBB2 testing and treatment irrespective of patient background. This could indicate increased provider adherence to evidence-based protocols and a successful push toward removing socioeconomic barriers, such as insurance coverage constraints or geographic limitations, that previously hampered equitable treatment access.

Moreover, evolving healthcare policies, including Medicare coverage expansions and value-based care initiatives, might have contributed to mitigating financial and systemic obstacles to receiving specialized oncology care. The analysis highlights older adults, a population segment often underrepresented in clinical trials and vulnerable to undertreatment, reflecting a crucial step toward inclusive cancer care.

Despite the advances, the study authors call for continued research to elucidate the precise clinical, social, and organizational factors that enabled this positive trend. Investigating patient-provider communication dynamics, health literacy, availability of specialty care centers, and community outreach programs could reveal actionable insights for further diminishing disparities.

Additionally, the study’s implications resonate with the broader oncology community striving for precision medicine that is truly accessible. Integrating genomic profiling and personalized treatment strategies requires not only scientific innovation but also equitable healthcare infrastructure capable of delivering these advances to diverse patient populations.

Experts emphasize that the fight against breast cancer is multifaceted, involving biological understanding, therapeutic innovation, and social justice. Elucidating how disparities in targeted therapy delivery have narrowed among Medicare beneficiaries provides a blueprint for similar efforts in other cancer subtypes and demographic groups, fostering a more just healthcare system.

The research, published in a prominent open-access medical journal, ensures immediate and unrestricted availability of its findings, facilitating dissemination among clinicians, policymakers, and patient advocacy groups. The authors stress that while progress is commendable, sustained commitment is essential to consolidate gains and expand equity across all dimensions of cancer care.

In closing, the evolving story of ERBB2-targeted therapy utilization signals hope for thousands of older adults battling breast cancer, highlighting the confluence of scientific progress and health equity. Continued collaborative efforts spanning research, clinical care, and health policy will be vital in translating these encouraging trends into universal standard care that leaves no population behind.

Subject of Research: Racial and ethnic disparities in receipt of ERBB2-targeted therapies among older Medicare beneficiaries with ERBB2-positive breast cancer

Article Title: Not provided

News Publication Date: Not provided

Web References: Not provided

References: (doi:10.1001/jamanetworkopen.2025.8086)

Image Credits: Not provided

Keywords: Breast cancer, Racial differences, Ethnicity, Older adults, Health insurance, Oncology, Medical treatments